Pancreatic Cancer Research

ResearcherLyon 1 UniversitéActive in the last 2 years

Cindy Neuzillet

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7037-7477; OpenAlex author ID A5008077511. Sources: ClinicalTrials.gov.

Their work

Papers
53 (first author 6, last author 10)
Trials
1
Grants
0
Labs led
1
Collaborators
135
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 2 papers · 2014: none · 2015: 5 papers · 2016: 2 papers · 2017: 1 paper · 2018: 4 papers · 2019: 4 papers · 2020: 6 papers · 2021: 5 papers · 2022: 3 papers, 1 trial · 2023: 6 papers · 2024: 2 papers · 2025: 6 papers · 2026: 5 papers

Papers 50 of 53

  1. Decoding the Integrated Stress Response of Pancreatic Cancer: Identifying a Serine-dependent Tumor Subset Under Metabolic Relationships With CAFs. Co-author DOI 10.1002/advs.202515740↗
  2. Toward precision chemotherapy in pancreatic ductal adenocarcinoma: molecular, transcriptomic and clinical determinants. Co-author DOI 10.1016/j.dld.2026.02.020↗
  3. Optimizing first-line NALIRIFOX and exploring the role of the microbiota in second-line pancreatic cancer treatment: the PRODIGE 105-GERCOR 116 PANORAMIX trial. Last author DOI 10.1016/j.dld.2026.10.006↗
  4. Current practices and challenges in the management of nonmetastatic pancreatic adenocarcinoma: results of an EORTC survey. Last author DOI 10.1016/j.esmogo.2026.100372↗
  5. Emergency integrative supportive care program for frail patients with advanced pancreatic cancer: A prospective GERCOR ARCAD study Co-author DOI 10.64898/2026.06.18.26355998↗
  6. Muscle Loss During First-Line Chemotherapy Impairs Survival in Advanced Pancreatic Cancer Despite Adapted Physical Activity. Co-author DOI 10.1002/jcsm.13595↗
  7. Redefining phenotypic intratumor heterogeneity of pancreatic ductal adenocarcinoma: a bottom-up approach. Co-author DOI 10.1002/path.6398↗
  8. Toward Precision Chemotherapy for Pancreatic Cancer Guided by Transcriptomic Signatures. Co-author DOI 10.1002/ueg2.70124↗
  9. Medical management of pancreatic cancer: from personalization to broadening treatment strategies. Co-author DOI 10.1016/j.ctrv.2025.102973↗
  10. Neoadjuvant approaches in non-metastatic pancreatic cancer: where do we stand? First author DOI 10.1016/s1470-2045(25)00421-8↗
  11. Digital and AI-assisted multimodal supportive care, combining physical activity, nutrition, and pain management during chemotherapy for advanced pancreatic can… Co-author DOI 10.1186/s12885-025-14867-6↗
  12. Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Pha… Co-author DOI 10.1200/jco.23.00795↗
  13. Trimodal Peri Operative Prehabilitation for patient with Upper Oesogastric and Pancreatic cancer: study protocol for a multicenter, two- cohort, open-label, si… Last author DOI 10.21203/rs.3.rs-4488963/v1↗
  14. Nutrition support in pancreatic cancer: An expert statement on practical implementation of French guidelines. Last author DOI 10.1016/j.clinre.2023.102153↗
  15. The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy. Last author DOI 10.1016/s2468-1253(23)00207-8↗
  16. Pacpaint: a histology-based deep learning model uncovers the extensive intratumor molecular heterogeneity of pancreatic adenocarcinoma. Co-author DOI 10.1038/s41467-023-39026-y↗
  17. Identification of a large intra-exonic deletion in BRCA2 exon 18 in a pancreatic ductal adenocarcinoma. Co-author DOI 10.1177/17588359221146132↗
  18. Pancreatic cancer orthotopic graft in a murine model. Co-author DOI 10.1590/acb382823↗
  19. Effect of Adapted Physical Activity in Patients With Advanced Pancreatic Cancer: The APACaP GERCOR Randomized Trial. Co-author DOI 10.6004/jnccn.2023.7065↗
  20. Periostin- and podoplanin-positive cancer-associated fibroblast subtypes cooperate to shape the inflamed tumor microenvironment in aggressive pancreatic adenoc… Co-author DOI 10.1002/path.6011↗
  21. PACpAInt: a deep learning approach to identify molecular subtypes of pancreatic adenocarcinoma on histology slides Co-author DOI 10.1101/2022.01.04.474951↗
  22. Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies. First author DOI 10.1177/17588359221118019↗
  23. Microbiome and pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.clinre.2020.101589↗
  24. European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Pancreatic Cancer. Co-author DOI 10.1016/j.ctrv.2021.102208↗
  25. Pharmacologic Normalization of Pancreatic Cancer-Associated Fibroblast Secretome Impairs Prometastatic Cross-Talk With Macrophages. Co-author DOI 10.1016/j.jcmgh.2021.01.008↗
  26. Translatome-based classification reveals a dual metabolic dependency of a new tumor subtype of pancreatic cancer Co-author DOI 10.1016/j.pan.2021.05.117↗
  27. Time from first seen in specialist care to surgery does not influence survival outcome in patients with upfront resected pancreatic adenocarcinoma. Co-author DOI 10.1186/s12893-021-01409-7↗
  28. [New drug approval: Olaparib - pancreatic cancer with BRCA germline mutation]. First author DOI 10.1016/j.bulcan.2020.06.009↗
  29. Time intervals to diagnosis and chemotherapy do not influence survival outcome in patients with advanced pancreatic adenocarcinoma. Co-author DOI 10.1016/j.dld.2020.03.014↗
  30. Correction: Schwann cells support oncogenic potential of pancreatic cancer cells through TGFβ signaling. Co-author DOI 10.1038/s41419-020-2262-1↗
  31. Maintenance therapies in metastatic pancreatic cancer: present and future with a focus on PARP inhibitors. Last author DOI 10.1177/1758835920937949↗
  32. FAK activity in cancer-associated fibroblasts is a prognostic marker and a druggable key metastatic player in pancreatic cancer. Co-author DOI 10.15252/emmm.202012010↗
  33. FOLFIRINOX De-Escalation in Advanced Pancreatic Cancer: A Multicenter Real-Life Study. Co-author DOI 10.1634/theoncologist.2020-0577↗
  34. Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/path.5224↗
  35. Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan. Co-author DOI 10.1016/j.clcc.2019.08.004↗
  36. Pancreatic cancer: Best supportive care. First author DOI 10.1016/j.lpm.2019.02.032↗
  37. Schwann cells support oncogenic potential of pancreatic cancer cells through TGFβ signaling. Co-author DOI 10.1038/s41419-019-2116-x↗
  38. [Maintenance strategies for advanced pancreatic cancer: Rationale and issues]. Last author DOI 10.1016/j.bulcan.2018.06.009↗
  39. Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). Co-author DOI 10.1016/j.dld.2018.08.008↗
  40. Prognostic stratification of resected pancreatic ductal adenocarcinoma: Past, present, and future. Last author DOI 10.1016/j.dld.2018.08.009↗
  41. Immune therapies in pancreatic ductal adenocarcinoma: Where are we now? Last author DOI 10.3748/wjg.v24.i20.2137↗
  42. Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1093/jnci/djx037↗
  43. Severe hyponatremia caused by nab-paclitaxel-induced syndrome of inappropriate antidiuretic hormone secretion: A case report in a patient with metastatic pancr… Co-author DOI 10.1097/md.0000000000004006↗
  44. Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers. Co-author DOI 10.1530/erc-16-0269↗
  45. State of the art and future directions of pancreatic ductal adenocarcinoma therapy. Co-author DOI 10.1016/j.pharmthera.2015.08.006↗
  46. [Pancreatic adenocarcinoma: 10 years of progress]. First author DOI 10.1016/s0007-4551(15)31219-4↗
  47. High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis. Co-author DOI 10.1111/his.12691↗
  48. Rationale and design of the Adapted Physical Activity in advanced Pancreatic Cancer patients (APACaP) GERCOR (Groupe Coopérateur Multidisciplinaire en Oncologi… Co-author DOI 10.1186/s13063-015-0983-8↗
  49. Targeting cancer cell metabolism in pancreatic adenocarcinoma. First author DOI 10.18632/oncotarget.4160↗
  50. Targeting the Ras-ERK pathway in pancreatic adenocarcinoma. Co-author DOI 10.1007/s10555-012-9396-2↗

Trials 1

  1. Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures Study director NCT05475366↗

Closest collaborators

The 25 strongest of 135 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Pascal R. Hammel · 21 shared papers, 2011–2026 · strength 2.34
  2. Jerome F. Cros · 17 shared papers, 2013–2026 · strength 2.09
  3. Marc Hilmi · 10 shared papers, 2018–2026 · strength 1.87
  4. Nelson Dusetti · 9 shared papers, 2021–2026 · strength 1.81
  5. Rémy Nicolle · 11 shared papers, 2021–2026 · strength 1.71
  6. Matthieu Delaye · 5 shared papers, 2023–2026 · strength 1.63
  7. Jean‐Baptiste Bachet · 9 shared papers, 2015–2026 · strength 1.34
  8. Louis de Mestier · 12 shared papers, 2015–2025 · strength 1.32
  9. Juan Iovanna · 7 shared papers, 2021–2026 · strength 1.29
  10. Déwi Vernerey · 7 shared papers, 2017–2026 · strength 1.16
  11. Anthony Turpin · 7 shared papers, 2018–2025 · strength 1.11
  12. Corinne Bousquet · 7 shared papers, 2019–2026 · strength 0.88
  13. Olivier Bouché · 7 shared papers, 2017–2026 · strength 0.87
  14. Annemilaï Tijeras‐Raballand · 9 shared papers, 2013–2023 · strength 0.79
  15. Victoire Cardot‐Ruffino · 5 shared papers, 2019–2026 · strength 0.78
  16. Brice Chanez · 3 shared papers, 2025–2026 · strength 0.77
  17. Ingrid Garajová · 2 shared papers, 2026 · strength 0.71
  18. Christine Jean · 5 shared papers, 2020–2026 · strength 0.69
  19. Nicolas Williet · 4 shared papers, 2018–2026 · strength 0.68
  20. Vinciane Rebours · 5 shared papers, 2016–2025 · strength 0.64
  21. Christophe Tournigand · 5 shared papers, 2015–2026 · strength 0.54
  22. Jérôme Raffenne · 4 shared papers, 2021–2025 · strength 0.53
  23. Nicolas Alejandro Fraunhoffer · 2 shared papers, 2025–2026 · strength 0.51
  24. Yvan Martineau · 4 shared papers, 2020–2026 · strength 0.49
  25. Stéphane Pyronnet · 4 shared papers, 2020–2026 · strength 0.49

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.